Literature DB >> 1901347

The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography.

B J Snow1, M Bhatt, W R Martin, D Li, D B Calne.   

Abstract

Movement disorders, including Parkinsonism, are prominent features of neurological Wilson's disease (WD). This suggests there may be dysfunction of the nigrostriatal dopaminergic pathway. To explore this possibility, five patients were studied using positron emission tomography (PET) with 18F-6-fluorodopa (6FD), and magnetic resonance imaging (MRI). We calculated striatal 6FD uptake rate constants by a graphical method and compared the results with those of 18 normal subjects. It was found that four patients with symptoms all had abnormally low 6FD uptake, and the one asymptomatic patient had normal uptake. PET evidence for nigrostriatal dopaminergic dysfunction was present even after many years of penicillamine treatment. It is concluded that the nigrostriatal dopaminergic pathway is involved in neurological WD.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1901347      PMCID: PMC1014291          DOI: 10.1136/jnnp.54.1.12

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  24 in total

1.  Nigrostriatal function in humans studied with positron emission tomography.

Authors:  W R Martin; M R Palmer; C S Patlak; D B Calne
Journal:  Ann Neurol       Date:  1989-10       Impact factor: 10.422

2.  Parkinson's disease: activity of L-dopa decarboxylase in discrete brain regions.

Authors:  K Lloyd; O Hornykiewicz
Journal:  Science       Date:  1970-12-11       Impact factor: 47.728

Review 3.  Biochemical changes in normal aging in human brain.

Authors:  L J Côté; L T Kremzner
Journal:  Adv Neurol       Date:  1983

4.  Computerized cranial tomography in presymptomatic and hepatic form of Wilson's disease.

Authors:  P Dettori; M G Rachele; L Demelia; A E Pelaghi; A M Nurchi; P Aromando; M Giagheddu
Journal:  Eur Neurol       Date:  1984       Impact factor: 1.710

5.  Advanced catecholaminergic disturbances in the brain in a case of Wilson's disease.

Authors:  P Nyberg; C G Gottfries; G Holmgren; S Persson; B E Roos; B Winblad
Journal:  Acta Neurol Scand       Date:  1982-01       Impact factor: 3.209

6.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations.

Authors:  C S Patlak; R G Blasberg
Journal:  J Cereb Blood Flow Metab       Date:  1985-12       Impact factor: 6.200

7.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data.

Authors:  C S Patlak; R G Blasberg; J D Fenstermacher
Journal:  J Cereb Blood Flow Metab       Date:  1983-03       Impact factor: 6.200

8.  Nuclear magnetic resonance (NMR) imaging in Wilson disease.

Authors:  G A Lawler; J M Pennock; R E Steiner; W J Jenkins; S Sherlock; I R Young
Journal:  J Comput Assist Tomogr       Date:  1983-02       Impact factor: 1.826

9.  Dopamine visualized in the basal ganglia of living man.

Authors:  E S Garnett; G Firnau; C Nahmias
Journal:  Nature       Date:  1983 Sep 8-14       Impact factor: 49.962

10.  Clinical assessment of 31 patients with Wilson's disease. Correlations with structural changes on magnetic resonance imaging.

Authors:  S Starosta-Rubinstein; A B Young; K Kluin; G Hill; A M Aisen; T Gabrielsen; G J Brewer
Journal:  Arch Neurol       Date:  1987-04
View more
  13 in total

Review 1.  Neuroimaging in Wilson disease.

Authors:  H N van Wassenaer-van Hall
Journal:  Metab Brain Dis       Date:  1997-03       Impact factor: 3.584

Review 2.  Copper and the brain noradrenergic system.

Authors:  Svetlana Lutsenko; Clorissa Washington-Hughes; Martina Ralle; Katharina Schmidt
Journal:  J Biol Inorg Chem       Date:  2019-11-05       Impact factor: 3.358

3.  Sleep disorders in Wilson disease: a systematic review and meta-analysis.

Authors:  Jinyang Xu; Qingqing Deng; Qingsong Qin; Alexandros N Vgontzas; Maria Basta; Chanyan Xie; Yun Li
Journal:  J Clin Sleep Med       Date:  2020-01-13       Impact factor: 4.062

4.  Profound midbrain atrophy in patients with Wilson's disease and neurological symptoms?

Authors:  K Strecker; J P Schneider; H Barthel; W Hermann; F Wegner; A Wagner; J Schwarz; O Sabri; C Zimmer
Journal:  J Neurol       Date:  2006-04-10       Impact factor: 4.849

5.  Concordant pre- and postsynaptic deficits of dopaminergic neurotransmission in neurologic Wilson disease.

Authors:  Henryk Barthel; Wieland Hermann; Regine Kluge; Swen Hesse; David R Collingridge; Armin Wagner; Osama Sabri
Journal:  AJNR Am J Neuroradiol       Date:  2003-02       Impact factor: 3.825

6.  Ocular motility and Wilson's disease: a study on 34 patients.

Authors:  I Ingster-Moati; E Bui Quoc; M Pless; R Djomby; C Orssaud; J P Guichard; F Woimant
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04-30       Impact factor: 10.154

7.  Dopamine D2 receptor binding and cerebral glucose metabolism recover after D-penicillamine-therapy in Wilson's disease.

Authors:  G Schlaug; H Hefter; B Nebeling; V Engelbrecht; P Weiss; G Stöcklin; R J Seitz
Journal:  J Neurol       Date:  1994-10       Impact factor: 4.849

8.  Relationship between striatal glucose consumption and copper excretion in patients with Wilson's disease treated with D-penicillamine.

Authors:  H Hefter; T Kuwert; H Herzog; G Arendt; W Stremmel; L E Feinendegen
Journal:  J Neurol       Date:  1993-11       Impact factor: 4.849

9.  Is blinking of the eyes affected in extrapyramidal disorders? An interesting observation in a patient with Wilson disease.

Authors:  Rajesh Verma; Rakesh Lalla; Tushar B Patil
Journal:  BMJ Case Rep       Date:  2012-11-27

10.  Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease.

Authors:  B Jeon; J M Kim; J M Jeong; K M Kim; Y S Chang; D S Lee; M C Lee
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-07       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.